

ATC codes: **C09DA07**

<b>Indication</b>	Essential hypertension <span>ICD11 code: <b>BA00.Z</b></span>
<b>INN</b>	Telmisartan + hydrochlorothiazide
<b>Medicine type</b>	Chemical agent
<b>List type</b>	Core
<b>Formulations</b>	Oral > Solid: 40 mg + 12.5 mg ; 80 mg + 12.5 mg ; 80 mg + 25 mg
<b>EML status history</b>	First added in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
<b>Sex</b>	All
<b>Age</b>	Adolescents and adults
<b>Therapeutic alternatives</b>	Medicines within the same pharmacological class can be used
<b>Therapeutic alternatives limitations</b>	Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for hydrochlorothiazide)
<b>Patent information</b>	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more <a href="#">about patents.</a> 
<b>Wikipedia</b>	<a href="#">Telmisartan + hydrochlorothiazide</a> 
<b>DrugBank</b>	<a href="#">Telmisartan</a>  , <a href="#">Hydrochlorothiazide</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroup, C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for amlodipine), be specified as therapeutic alternatives under the square box listing for telmisartan + hydrochlorothiazide on the EML.

